ROSSO-in-praxi: a Self-monitoring of Blood Glucose-structured 12-week Lifestyle Intervention Significantly Improves Glucometabolic Control of Patients with Type 2 Diabetes Mellitus
Overview
Pharmacology
Affiliations
Background: As healthy diet and physical activity can improve glucometabolic control in patients with type 2 diabetes, lifestyle changes should be the basis for each therapy. The only tool to visualize immediate effects of food pattern and exercise on blood glucose levels is self-monitoring of blood glucose (SMBG). Therefore, the aim of the 12-week lifestyle intervention ROSSO-in-praxi was to evaluate the impact of an SMBG-structured motivation and education program on glucometabolic and health parameters in diabetes patients not treated with insulin.
Methods: Participants (n = 405) generated a seven-point blood glucose diurnal profile every 4 weeks, including actual weight, waist circumference, and steps/day. At baseline and the end of the study, glycated hemoglobin A1c (HbA1c), blood pressure, and cholesterol levels, lifestyle changes, and well-being (SF36 and Center for Epidemiologic Studies Depression Scale questionnaires) were assessed.
Results: Three hundred twenty-seven participants (81%) completed the program and significantly improved quality of diet and physical activity, accompanied by an increase of >2,300 steps/day. Participants significantly reduced weight, body mass index, waist circumference, blood glucose, blood pressure, low-density lipoprotein cholesterol, and HbA1c by 0.3% (all P < 0.001), accompanied by increased physical and mental health and reduced depression measurements. Weight loss was significantly associated with overall improvements of glucometabolic and health parameters and mean reduction of 0.05% HbA1c/kg.
Conclusions: The evaluated SMBG-structured lifestyle intervention is applicable to motivate individuals with type 2 diabetes for lifestyle changes. Integration of this short-term, highly motivational, and low-cost intervention into basic therapy for patients without insulin therapy could strengthen patient empowerment in order to change lifestyle and to improve glucometabolic and general health.
Holmes-Truscott E, Baptista S, Ling M, Collins E, Ekinci E, Furler J Front Clin Diabetes Healthc. 2023; 4:1177030.
PMID: 37153750 PMC: 10157033. DOI: 10.3389/fcdhc.2023.1177030.
Su B, Chen Y, Shen X, Guo J, Ding Y, Ma X J Med Internet Res. 2023; 25:e38680.
PMID: 37097724 PMC: 10170357. DOI: 10.2196/38680.
Lin J, Li X, Jiang S, Ma X, Yang Y, Zhou Z Int J Endocrinol. 2020; 2020:7249782.
PMID: 33224195 PMC: 7671790. DOI: 10.1155/2020/7249782.
Weight Reduction by the Low-Insulin-Method-A Randomized Controlled Trial.
Rohling M, Martin K, Ellinger S, Schreiber M, Martin S, Kempf K Nutrients. 2020; 12(10).
PMID: 33007918 PMC: 7601801. DOI: 10.3390/nu12103004.
Freckmann G, Baumstark A, Jendrike N, Mende J, Schauer S, Link M J Diabetes Sci Technol. 2020; 16(5):1076-1088.
PMID: 32814455 PMC: 9445332. DOI: 10.1177/1932296820948873.